Latest Payments News

Mayfield Group Holdings Limited has announced a fully franked ordinary dividend of AUD 0.01 per share, signaling steady returns for shareholders with payment scheduled for mid-February.

Mayfield Group Holdings has declared a $5 million special dividend alongside its interim payout, signaling robust financial health and confidence in sustained growth.

Argosy Minerals Limited reported a net cash outflow in its December 2024 quarter, driven by exploration and evaluation expenses, ending with nearly $6 million in cash reserves.

Brockman Mining Limited's latest quarterly report reveals steady progress on the Marillana Project, underpinned by joint ventures with Mineral Resources and Hancock Prospecting, alongside key infrastructure developments at Port Hedland.

SIV Capital Limited reported a negative operating cash flow for Q2 FY25 and remains suspended from ASX trading due to compliance issues, while actively exploring acquisition opportunities.

Energy World Corporation Ltd. reports significant board changes and strategic committee formations as it navigates a quarter marked by operational cash outflows but maintains a solid cash reserve.

Key Petroleum Limited progresses Potential Commercial Area applications for ATPs 920 and 924 in Queensland’s Cooper Eromanga Basin, supported by a recent capital raise despite a constrained cash balance.

Oneview Healthcare reported a robust Q4 2024 cash flow update, bolstered by a significant equity raise and expanding partnerships, positioning the company for accelerated growth in 2025.

Pengana Global Private Credit Trust has announced an ordinary unfranked dividend of AUD 0.0116 per unit, payable in mid-February 2025, reflecting steady income distribution for investors.

ENRG Elements Limited reported a $586,000 net cash outflow for the December quarter, offset by a $2.02 million equity raise, boosting its cash reserves to $2.52 million.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.